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Recent systematic reviews of diagnostic studies have
reported frequent methodological shortcomings. These
include failure to report participants’ age and gender,
state of disease, and study eligibility criteria, as well as
use of inappropriate study design, and lack of appropri-
ate blinding. Studies with adequate design should clearly
define the reference standard for the study including
definitions of disease and non-disease states. The refer-
ence standard should be well-accepted and reproducible,
have cut-points that are defined before-hand, and should
not incorporate the results of the test being evaluated.
The study should assess the tests in patients who have
not yet received treatment unless it is certain that treat-
ment does not affect test results. Those performoing the
test should be blinded to the clinical diagnoses and
while those making the clinical diagnoses should be
blinded to test results. The analysis should use a 2x2
table that can evaluate sensitivity/specificity, predictive
value and likelihood ratio.
Evaluation of a new diagnostic tool should follow a
standardized approach with four phases, similar to the
evaluation for testing new medications to provide the evi-
dence needed for FDA licensing. Phase one studies
should provide information on technical aspects of the
test, including its reproducibility, as well as the expected
range of values when the test is performed in normal
healthy subjects. Participants should be healthy volun-
teers although gender, age and ethnic origin should be
considered when selecting these volunteers. Phase two
studies are of two types: Phase 2a is a case control study
in which the test is performed in patients with disease
and healthy controls. Phase 2B is a cohort study; conse-
cutive patients who are being investigated for the disease
or condition which the new test is intended to diagnose
are enrolled. Case control studies are essentially proof of
concept studies, as they will over-estimate test accuracy -
results in practice are usually worse than in case-control
studies due to spectrum bias. The cohort design should
be prospective and the population enrolled should be
suspected of having the disease and should be a consecu-
tive series, or randomly selected patients. No exclusions,
due to a failed test or unclear diagnosis, should be per-
mitted. Phase three studies are randomized trials.
Patients suspected of having the disease, are randomized
to receive the test, or not. Unfortunately these studies
pose several ethical issues, and are not well accepted by
provider and patients - often resulting in a highly selected
study sample. Phase four studies should provide informa-
tion from a societal perspective—cost effectiveness, dis-
ease modeling, and data base studies.
Published: 17 December 2010
doi:10.1186/1753-6561-4-S3-O13
Cite this article as: Menzies: Evaluating new diagnostic tests in the field –
are we doing it right?. BMC Proceedings 2010 4(Suppl 3):O13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Correspondence: dick.menzies@mcgill.ca
Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
Menzies BMC Proceedings 2010, 4(Suppl 3):O13
http://www.biomedcentral.com/1753-6561/4/S3/O13
© 2010 Menzies; licensee BioMed Central Ltd.
